Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 @FilipaLynce X Profile

Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸

@FilipaLynce

Followers

2K

Following

5K

Media

48

Statuses

630

Breast Oncologist @ Dana-Farber Cancer Institute. Director, Dana Farber IBC Program. DFCI Center for BRCA and related genes. Alliance EO. Tweets are my own.

Boston, MA

Joined November 2014

Don't wanna be here? Send us removal request.

Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸

@FilipaLynce

2 years

So grateful for this amazing team of patients, advocates and colleagues who work every day to improve the lives of patients diagnosed with IBC! Team IBC at Jimmy Fund Walk 2023 @IBC_DanaFarber @DFCI_BreastOnc @TalkIBC

6

35

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

6 days

We are leading a phase 2 study, called #TRUDI, to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn if the intervention works in stage III, HER2-expressing #InflammatoryBreastCancer. https://t.co/WCVCnj3jix

0

11

18

Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸

@FilipaLynce

3 days

Great presentation by @antgiorda on promising therapies under development for metastatic TNBC. This is an important area of unmet need. Our patients need more treatment options. @DFCI_BreastOnc #PBCClive25

0

4

15

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

4 days

The new ZAP-IT study is evaluating the safety and effectiveness of #Azenosertib (ZN-c3) in combination with carboplatin and pembrolizumab in metastatic #TripleNegativeBreastCancer. For more information call 877-338-7425 or visit: https://t.co/Ptl988BXHv PI: @FilipaLynce #TNBC

1

4

12

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

20 days

New Paper: Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive #InflammatoryBreastCancer: a multicenter retrospective study. 👉 https://t.co/hUNb70U4Ke @IBCradiation #FainaNakhlis @jenniferbellon2 @FilipaLynce @teamoncology #IBC #BreastCancer

1

16

49

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

1 month

The new ZAP-IT study is evaluating the safety and effectiveness of #Azenosertib (ZN-c3) in combination with carboplatin and pembrolizumab in metastatic #TripleNegativeBreastCancer. For more information call 877-338-7425 or visit: https://t.co/Ptl988Cvx3 PI: @FilipaLynce #TNBC

0

6

11

Dr Sarah Sammons

@drsarahsam

1 month

This is where the importance of government cancer funding comes in. My brilliant colleague designing a large trial to give less trastuzumab to HER2+ patients who achieve pCR.

Alliance for Clinical Trials in Oncology

@ALLIANCE_org

1 month

New Trial! @adawaksmd of @DanaFarber leads @ALLIANCE_org A012303 (ShortStop-HER2), a study exploring if less treatment is needed after surgery for people w/early-stage HER2+ #breastcancer who had no cancer left after chemo + HER2 therapy (before surgery). https://t.co/LdlcuS8BN0

2

14

45

Harold J. Burstein, MD, PhD, FASCO

@DrHBurstein

2 months

Extraordinary talk. One of the highlights of our program!

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

2 months

Dr. Marleen Kok (@lab_kok) delivered an excellent #HarvardBreastCancerCourse Schlager Lecture on #Immunotherapy in Early #BreastCancer. The Schlager lectureship brings in world leading cancer investigators working in women's cancers.

0

10

33

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

2 months

https://t.co/6eY7Gf8SF5

1

2

8

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

2 months

Dr Hal Burstein (@HaroldBurstein) moderated the Early #BreastCancer Tumor Board at the #HarvardBreastCancerCourse, where breast oncology experts, @EMittendorfMD #FainaNakhlis @adawaksmd @DrBBychkovsky, @FilipaLynce and #JuliaWong, discussed early breast cancer management through

0

6

17

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

2 months

Dr. Filipa Lynce (@FilipaLynce) discussed #InflammatoryBreastCancer on Day 1 of the #HarvardBreastCancerCourse, covering clinical challenges and new #IBC research in this aggressive subtype of #BreastCancer. @IBC_DanaFarber

1

5

12

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

2 months

The #HarvardBreastCancerCourse starts on Thursday! 📅July 17 & 18 📍Westin Copley Place, Boston, MA The @harvardmed #BreastCancer course is well suited for medical, surgical & radiation oncologists; breast & general surgeons; internists; physician assistants; nurse practitioners,

1

12

18

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

2 months

Check out this recent paper on #InflammatoryBreastCancer, it examines the clinicogenomic characterization of #IBC. 👉 https://t.co/reo1YSZPNP @npriedig @DrBBychkovsky @jenniferbellon2 @TariKingMD @DrEricWiner @lmsholl @stolaney1 @nlinmd @FilipaLynce @DrRBarroso

1

21

37

Dana-Farber

@DanaFarber

2 months

We’re proud to be included in @Newsweek’s America’s Greatest Workplaces by State 2025 list. This recognition reflects our ongoing commitment to fostering a supportive, inclusive, and mission-driven workplace – one where every team member has the opportunity to thrive and grow.

0

7

26

Dana-Farber

@DanaFarber

2 months

A new study led by Dipanjan Chowdhury, PhD, co-director of our Center for BRCA and Related Genes, uncovers why some cancers resist PARP inhibitors. The findings could help guide more personalized treatment strategies. Learn more about the study:

blog.dana-farber.org

Published: June 10, 2025Updated: June 11, 2025Written by: Beth DoughertyThere are two ways to fix things: the quick way and the careful one. In cancer, cells with BRCA1 mutations tend to choose the...

0

4

25

Jennifer Guerriero, PhD

@JennGuerriero

3 months

We call ourselves the 3 musketeers. Today we scored 4% on an MPI R01 that will investigate targeting macrophages in Brca-associated breast cancer. So proud of this dream team. Team science always wins. @FilipaLynce @GShapiroMDPhD @BrighamSurgery @DFCI_BreastOnc

13

9

149

Tess O'Meara, MD, MHS

@tess_omeara

3 months

More fun with @OncLive @jhaveri_komal @KalinskyKevin discussing controversial topics in recent breast cancer trials. Hearing clinical insights from these thoughtful, dedicated mentors & friends is a day well spent!!! Glamor shot by @FilipaLynce 📸

OncLive.com

@OncLive

3 months

That’s a wrap from #BridgingTheGaps Breast Cancer! Today’s meeting brought together leaders in breast cancer care to build consensus, drive innovation, and advance equity in treatment. Thank you to all who joined! 🔬🧬 Tune in for more meeting updates: https://t.co/NVIgC4PPzq

0

3

15

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

3 months

@SusanGKomen, the world’s leading #BreastCancer organization, is awarding $10.8 million in new research grants. “Komen’s commitment to breast cancer research comes at a pivotal time and will drive meaningful advances in our understanding of the disease and care of patients,” said

0

4

20

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

3 months

Congratulations to Dr. Filipa Lynce (@FilipaLynce) recipient of the Women’s Health Collaboration Award from the @MALifeSciences! This award supports collaborative projects that aim to improve the discovery, technical innovation, and analysis of datasets to answer pressing life

3

11

43

Dr Sarah Sammons

@drsarahsam

3 months

Study that went under the radar at ASCO. WBRT with hippocampal sparing and memantine versus SRS for 5-20 brain metastases. Same Overall survival, Lower Symptom Burden and Life Interference with SRS, Better KPS with SRS. New standard of care! Congrats Dr. Aizer on this amazing

10

52

96

Harold J. Burstein, MD, PhD, FASCO

@DrHBurstein

3 months

Registration open for virtual or in-person participation. A remarkable, thorough and efficient two days of breast cancer updates from the nation's leading breast oncology program @DFCI_BreastOnc @DanaFarber

OncoDaily

@oncodaily

3 months

@DFCI_BreastOnc @harvardmed @DrHBurstein We would like to inform you that your post has been published on https://t.co/igx4msE1Ge. Thank you for sharing. https://t.co/fqLOmTBheb

4

3

17